title: Update on the CNS adverse effects of Sustiva (efavirenz).
authors.forename: Kiron
authors.initials: K
authors.lastname: Punwani
authors.forename: Shannon
authors.initials: S
authors.lastname: Suedkamp
authors.forename: Diem
authors.initials: D
authors.lastname: Nguyen
authors.forename: Jessica C
authors.initials: JC
authors.lastname: Song
mesh_terms: D000293:Adolescent; D000328:Adult; D000480:Alkynes; D048588:Benzoxazines / Q000009:adverse effects* / Q000493:pharmacokinetics; D002490:Central Nervous System / Q000187:drug effects*; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D044382:Population Groups; D011358:Product Surveillance, Postmarketing; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz